IgA1 deposition may induce NLRP3 expression and macrophage transdifferentiation of podocyte in IgA nephropathy

Wei Peng1,2†, Gai-qin Pei1†, Yi Tang1,3*, Li Tan1 and Wei Qin1,3*

Abstract
Background: The NLRP3 inflammasome plays an important role in mediating podocyte injury in various kidney diseases. The aim of this study was to investigate whether NLRP3 expression associated with podocyte injury was involved in the pathogenesis of IgA nephropathy (IgAN).

Methods: NLRP3 inflammasomes and macrophage marker (F4/80) were detected in the renal tissues of IgAN patients. Association between kidney NLRP3 levels and the clinical feature of IgAN patients was analyzed. Podocytes were incubated with serum containing dys-glycosylated IgA1 protein isolated from IgAN patients. Expression of NLRP3 inflammasomes, F4/80, inflammatory cytokine and renal fibrosis marker were measured using RT-PCR and Western blotting.

Results: Renal NLRP3 inflammasome expression was significantly increased in IgAN patients compared to normal control tissues. Moreover, co-expression of NLRP3 and F4/80 could be observed in the podocytes of IgAN patients. Patients with eGFR < 60 ml/min/1.73 m² had remarkably higher tubular NLRP3 expression (P < 0.05), while patients with gross proteinuria (≥ 3.5 g/day) had a significantly higher glomerular NLRP3 expression (P < 0.05). Further analysis indicated that dys-glycosylated IgA1 isolated from IgAN patient serum could induce podocyte expression of NLRP3 and the macrophage marker F4/80, which could lead to induction of an inflammatory reaction (increased expression of ICAM-1) and fibrosis (increased expression of α-SMA).

Conclusion: Dys-glycosylated IgA1 isolated from IgAN patient serum could induce NLRP3 expression in podocytes and initiate podocyte macrophage transdifferentiation (PMT). After PMT, podocytes secrete proinflammatory cytokines that can contribute to the inflammation cascade and renal fibrosis changes associated with IgAN.

Keywords: IgA nephropathy, NLRP3, Podocyte macrophage transdifferentiation

Background
Immunoglobin A nephropathy (IgAN) is characterized by the IgA accumulates in the kidneys and is the most prevalent cause of primary glomerulonephritis worldwide [1]. 15–40% of IgAN patients will go on to develop end-stage renal disease (ESRD) within 10–20 years of onset of IgAN [2]. NLRP3 (NOD-like receptor, pyrin domain-containing 3) is an important component of the innate immune system. Previous reports have found that NLRP3 is highly expressed in renal tubular epithelial cells in IgAN and its increased expression is associated with tubular injury. The expression of NLRP3 and activation of its downstream signaling proteins in glomeruli has been described by several studies for various renal diseases [3–6]. In lupus nephritis, the NLRP3 inflammasome was found to be activated in podocytes from biopsy and urine samples, which promoted podocyte injury and proteinuria [4]. Increased NLRP3 inflammasome activity is also implicated in podocyte injury and glomerular sclerosis in hyperhomocysteinemia [7]. Podocyte injury is known to be an important factor for progression of
glomerulosclerosis in IgAN [8]. Recent studies have shown that podocytes can acquire macrophage-like functions and activate specific T cell responses (podocyte macrophage transdifferentiation, or PMT), contributing to development of increased inflammation; these findings indicate that podocytes and macrophages may share lineage commitment [9]. Whether this newly described function is relevant to podocytes in the context of IgAN has yet to be explored. Therefore, we conducted this preliminary study to clarify whether activity of the NLRP3 inflammasome or PMT is involved in podocyte injury and pathogenesis in IgAN.

**Methods**

**Subjects**

Twenty-four patients with primary IgAN confirmed via renal biopsy were recruited from West China Hospital of Sichuan University. Patients with chronic systemic diseases (systemic lupus erythematosus, diabetes mellitus, Henoch–Schönlein purpura, liver cirrhosis, etc.) or advanced renal failure (estimated glomerular filtration rate (eGFR) \(\leq 15 \text{ ml/min/1.73 m}^2\)) were excluded. eGFR levels were calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. Clinical information (gender, age, disease history) and laboratory data (serum albumin, serum creatinine, uric acid, 24 h urinary protein and eGFR levels) were collected at the time of biopsy. Histologically normal kidney tissues dissected adjacent to renal tumor were used as controls \((n = 8)\). Written informed consent was obtained from all subjects and the study was approved by the Ethics Committee of West China Hospital of Sichuan University.

**Isolation of serum IgA1**

IgA1 was isolated from the serum of IgAN patients using jacalin affinity chromatography (Sigma, Saint Louis, MO, USA) and a Sephacryl S-200 molecular sieve column (GE Healthcare) as previously described [10, 11]. Briefly, jacalin columns were prepared using jacalin-immobilized agarose resin. Serum samples were diluted 1:1 with 175 mM Tris–HCl (pH 7.4), filtered through a 0.2 μm Corning syringe filter, applied to the column, and then washed with 175 mM Tris–HCl (pH 7.4) until the optical density at 280 nm was less than 0.01. Bound IgA1 was then eluted with 0.1 M melibiose in 175 mM Tris–HCl (pH 7.4) until the optical density returned to 0.01. The eluted fractions were pooled, concentrated and applied to a Sephacryl S-200 molecular sieve column. The IgA1 content of the samples was verified by Western blotting and samples were then kept frozen at \(-80^\circ\text{C}\) for future studies.

**In vitro IgA1 stimulation of MPC-5 cells**

The mouse podocyte cell line MPC-5 was kindly provided by Professor Ping FU. Experiments were performed using low passage (passage 10–18), growth-restricted, conditionally immortalized MPC-5 cells as previously described [11]. To maintain cells in the undifferentiated state, cells were grown under “growth permissive” conditions, which involved growing cells at 33°C in the presence of IFN-γ (50 U/ml). To induce podocyte differentiation, cells were grown under “restrictive conditions” in the absence of IFN-γ at 37°C under 5% CO₂ for more than 12 days. The differentiated cells were incubated overnight in RPMI 1640 containing 0.5% FBS, which
was followed by stimulation with or without 0.5 mg/mL serum IgA1 isolated as previously described for 36 h.

RT-PCR and Western blot analysis
RNA was extracted from cultured cells using TriZOL reagent (Invitrogen) and cDNA was prepared according to the manufacturer's instructions (Bio-радиScript™ Reverse Transcriptase). Primers used were as follow: mouse GAPDH (forward 5- GCCATGGCCTTCCGTG TTC-3; reverse 5-GATGTCATCACTTGGCCAGTTT -3); mouse NLRP3 (forward 5-AGAGGCTACAGTTGG GTGAAATG-3; reverse 5-CCACGCTACAGGAAAT CTC-3); mouse α-SMA (forward 5-GTCCCCAGACATC AGGGAGTAA-3; reverse 5-TGGGATACCTACGGTGCA GGA-3); mouse ICAM-1 (forward 5-TCAGGTATCCCAT CCATCCAGAGA-3; reverse 5-AGCTCATCTTTCAGC CACTGAGTCTC-3). RT-PCR was performed as previously described [12]. The expression level of target genes was calculated using the delta-CT method. The supernatants of protein lysates from cultured podocyte were collected for Western blot analysis. The primary antibodies used were mouse NLRP3 (R&D Systems, 1:100), mouse ICAM-1 (R&D Systems, 1:300), mouse α-SMA (Cell Signaling Technology, 1:500), mouse F4/80 (Abcam, 1:50), and mouse β-tubulin (Santa Cruz Biotechnology, 1:1000). Horseradish peroxidase-conjugated rabbit or goat IgG antibodies were used as secondary antibodies (Cell Signaling Technology). Densitometric results were analyzed with Image J software. All protein measurements were normalized to β-tubulin.

Statistical analyses
Statistical analysis was performed using SPSS 22.0. The data were expressed as mean ± SD or as medians (range). Significant differences were assessed using either at-test or one-way ANOVA. A nonparametric Mann–Whitney U test was performed to compare the integrated optical density between experimental groups. A two-tailed P < 0.05 was considered statistically significant.

Results
Podocytes express NLRP3 in IgAN
Immunofluorescent staining analysis revealed that NLRP3, podocalyxin (a major sialoprotein in podocytes) and IgA1 co-localized in the podocytes of IgAN patients. However, NLRP3 staining was not detected in normal control kidney samples (Fig. 1). While deposition of IgA in the glomerular mesangium is a hallmark of IgAN, our finding suggest that IgA1 may accumulate specifically in podocytes, where it may stimulate NLRP3 expression in IgAN patients. Direct deposition of IgA in IgAN patient podocytes has not been described in the literature previously, so this finding may help provide an oval clue to better understanding the pathogenesis of IgAN. Further immunohistochemistry staining analysis showed that NLRP3 could be detected in the glomeruli and tubules of renal biopsy tissue from IgAN patients, while only very low levels of NLRP3 could be detected in normal renal tissue (Fig. 2). We observed that NLRP3 was significantly increased in the glomeruli (0.016 ± 0.0075 vs 0.004 ± 0.0012, P < 0.001) and tubules (0.033 ± 0.0136 vs 0.007 ± 0.0013, P < 0.001) IgAN patients compared to controls (Fig. 2).

Expression of NLRP3 varies with clinical manifestation of IgAN
The association between expression of NLRP3 in glomeruli and tubules and patients’ clinical manifestation of IgAN were analyzed. We found that NLRP3 expression in different regions of the kidney was significantly different in IgAN patients grouped based on clinical features. Significantly higher glomerular NLRP3 levels were detected in patients with more severe proteinuria (≥ 3.5 g/day) compared to patients with less proteinuria (< 3.5 g/day) (0.021 ± 0.0069 vs 0.013 ± 0.0069, P = 0.013). However, tubular NLRP3 expression levels were similar between these two groups (0.036 ± 0.0153 vs 0.031 ± 0.0137, P = 0.360) (Fig. 3). Significantly higher renal tubular NLRP3 expression levels were detected in patients with severe renal dysfunction (eGFR < 60 ml/ min/1.73 m²) than in patients with less severe renal dysfunction (eGFR ≥ 60 ml/min/1.73 m²) (0.042 ± 0.0171 vs 0.029 ± 0.0112, P = 0.034). However, glomerular NLRP3 expression levels were similar between these two groups (0.019 ± 0.0075 vs 0.0149 ± 0.0080, P = 0.318) (Fig. 3).

α-SMA and ICAM-1 expression is increased in glomeruli of IgAN patients
α-SMA and ICAM-1 were expressed in the glomeruli of IgAN patients (Fig. 4). Further analysis indicated that the ICAM-1 protein expression level (IHC stain AIOD value) in glomeruli [0.03165 ± 0.0080, P = 0.009] and the α-SMA protein expression level in glomeruli (0.0255 ± 0.0066 vs 0.003 ± 0.0027, P < 0.001) of IgAN patients were significantly higher than in controls.

Serum IgA1 may induce PMT in IgAN
To examine the expression of macrophage markers in podocytes from IgAN patients, a double staining with an antibody against the podocyte marker podocalyxin and an antibody against the established macrophage marker F4/80 was performed. We observed that F4/80 could be detected in podocalyxin-positive podocytes in biopsy samples from IgAN patients. However, only the podocyte marker and not the macrophage marker could be detected in the control patient biopsy samples
(Fig. 5). In order to investigate the role of NLRP3 and F4/80 in podocytes, MPC-5 cells were stimulated with serum IgA1 purified from IgAN patients. After 36 h of stimulation, the mRNA and protein level of NLRP3 and F4/80 increased significantly compared to control (Fig. 6). Immunofluorescent staining also indicated that serum IgA1 stimulation could induce NLRP3 and F4/80 expression in MPC-5 cells (Figs. 7, 8). Co-localization of podocalyxin and IgA1 was present in MPC-5 cells (Fig. 9), indicating that IgA1 accumulated intracellularly. Furthermore, after serum IgA1 stimulation, the protein levels of the inflammatory mediator ICAM-1 and the
myofibroblast marker α-SMA increased remarkably compared to unstimulated cells (Fig. 6). These results suggested that serum IgA1 may induce NLRP3 expression and initiate PMT, which could promote increased inflammation and renal fibrosis.

**Discussion**

IgAN is one of the most common causes of primary glomerulonephritis and a leading cause of ESRD. However, the exact pathogenic mechanism underlying IgAN remains largely unknown. It is well accepted that development of proteinuria is a major risk factor for disease progression, and is worsened by diminished podocyte function and survival [13]. Previous studies have indicated that dys-glycosylated IgA1 deposits in the mesangial and para-mesangial area of the glomeruli can induce apoptosis and transdifferentiation of podocytes in IgAN, which in turn leads to dysfunction of the renal filtration barrier and development proteinuria [14]. However, the exact mechanism by which dys-glycosylated IgA1 induces podocyte dysfunction in IgAN is still unknown.

Recently, several studies have suggested that NLRP3 could mediate podocyte dysfunction in several different
Fig. 5 F4/80 localizes to podocytes in human IgAN. Dual labeling for F4/80 (red) and podocalyxin (green) was performed. Nuclear staining with DAPI (blue) is shown in merged images. Original magnification: ×400. IgAN IgA nephropathy, Ctrl control.

Fig. 6  

a IgA1-stimulated mRNA expression of NLRP3, α-SMA and ICAM-1 mRNA expression in MPC-5 cells.  

b IgA1-stimulated protein expression of NLRP3, α-SMA, ICAM-1 and F4/80 protein expression in MPC-5 cells. *P < 0.05
kidney diseases [15–17]. NLRP3 is a critical regulator of inflammation and is activated upon exposure to pathogens or damage-associated molecular patterns (PAMPs or DAMPs) and environmental irritants [18]. Research focused on understanding the relationship between podocytes and NLRP3 activity may help improve understanding of IgAN pathogenesis and identify novel therapeutic targets. In this study, we found that NLRP3 expression was significantly increased in the glomeruli and tubules in IgAN patient renal biopsy tissues when compared to normal kidney tissues, which is consistent with previous findings [19]. Interestingly, NLRP3 expression levels were found to vary in IgAN patients with different amounts of renal dysfunction and proteinuria. Significantly higher NLRP3 levels were detected in the renal tubules of patients with lower eGFR levels (<60 ml/min/1.73 m²). Moreover, significantly higher NLRP3 levels were detected in the glomeruli of IgAN patients with severe proteinuria (≥3.5 g/day). Our findings suggest there is differential expression of NLRP3 based on the clinical manifestation of IgAN, which should be validated by future studies with larger sample sizes. Only one study
has previously reported a positive correlation between NLRP3 expression and proteinuria in patients with glomerulonephritis; however, patients with several types of primary glomerular disease were included in that study [6].

Our findings indicated that NLRP3 expression was localized to podocytes in kidney biopsies from IgAN patients. Previously, IgA deposition was known to occur in the mesangial region and occasionally seen in glomerular capillary walls, but was never described in podocytes. We observed co-localization of IgA and podocalyxin, which provides evidence that IgA can accumulate in podocytes. Moreover, we also demonstrated that podocalyxin and IgA co-localize in MPC-5 cells. While we did not do experiments to confirm direct binding, the findings in this study provide strong evidence that intracellular IgA1 accumulation in podocytes could account for podocyte phenotypes associated with IgAN. Our in vitro experiments suggest that serum IgA1 isolated from IgAN patients is sufficient to increase NLRP3 expression and pro-inflammatory cytokine expression in podocytes. These results indicate that IgA accumulation in podocytes may induce NLRP3 expression and initiate podocyte injury, transdifferentiation and subsequent inflammatory response, thus promoting the development of proteinuria in IgAN.

For decades, podocytes injury has been seen as a hallmark of glomerulonephritis. Impaired podocyte structure and function leads to proteinuria and renal failure in variety of renal diseases, including diabetic nephropathy, lupus nephritis and membranous nephropathy. However, increasing evidence has indicated that podocytes may actively participate in immune-mediated damage by recruiting inflammatory cells or even acting as antigen-presenting cells or macrophages [20, 21]. It was reported that podocytes may clear immune complexes from the glomerular basement membrane and participate in development of renal inflammation and fibrosis [22]. In this study, we found that the podocytes of IgAN patients could express the macrophage marker F4/80. We also found that serum IgA1 from IgAN patients could stimulate the expression of NLRP3 and F4/80 in MPC-5 cells, which resulted in increased expression of the inflammatory mediator ICAM-1 and the myofibroblast marker α-SMA. The expression of α-SMA and ICAM-1 was also significantly higher in the glomeruli of IgAN patients, indicating the occurrence of mesenchymal transdifferentiation and induction of inflammation. These observations suggest that podocytes stimulated with dys-glycosylated IgA1 may acquire macrophage-like functions and undergo trans-differentiation into inflammatory cells that release pro-inflammatory cytokines and participate in pathological changes that drive IgAN. Unfortunately, our present study is unable to implicate the specific role of NLRP3 which might be played in driving PMT. PMT is a relatively new concept that is indicated by some findings in this preliminary study. We intend to carry out further research in transgenic mice to validate the hypotheses about PMT and IgAN generated by the findings in this study. Previous investigations have shown that NLRP3 can be activated in macrophages and regulate their function [23]. The increased NLRP3 expression described in the present study could be the result

Fig. 9 Colocalization of IgA1 and podocalyxin in MPC-5 cells stimulated by IgA1. Dual labeling of IgA1 (red) and podocalyxin (green) was performed. Original magnification: ×400
of PMT or some other aspect of IgAN pathogenesis. Whether NLRP3 activation and expression is involved in podocyte transdifferentiation in the context of IgAN needs to be evaluated in future studies.

Our observations provide new evidence for a novel and unexpected role of podocytes in IgAN pathogenesis. Based on our findings, we hypothesize that in the context of IgAN, serum dys-glycosylated IgA1 may stimulate podocytes directly and induce the expression of NLRP3, which will initiate PMT. As a result of PMT, podocytes will acquire macrophage-like characteristics and release inflammatory cytokines, which will promote inflammation and renal fibrosis. The current study is provides evidence to support this hypothesis, but further study is required for validation.

Conclusion
In conclusion dys-glycosylated IgA1 isolated from IgAN patient serum can induce NLRP3 expression in podocytes, which may initiate podocyte macrophage transdifferentiation (PMT). After PMT, podocyte scan secrete proinflammatory cytokines that could contribute to promoting the inflammation cascade and renal fibrosis associated with IgAN.

Abbreviations
IgAN: immunoglobulin A nephropathy; ESRD: end-stage renal disease; NLRP3: NOD‑like receptor, pyrin domain‑containing 3; eGFR: estimated glomerular filtration rate; CKD‑EPI: chronic kidney disease epidemiology collaboration; IOD: integrated optical density; PMT: podocyte macrophage transdifferentiation.

Acknowledgements
Not applicable.

Authors’ contributions
WQ and YT conceived and designed the study. WP and GP conducted in vitro experiments and data analysis. WP and WQ performed human kidney biopsy collection and analysis. WP and WQ wrote the manuscript. All authors read and approved the final manuscript.

Funding
This work was partly supported by the National Natural Science Foundation of China (No. 81970612) and Key Science Project Foundation of Sichuan Province (No. 17ZD013 and 19ZDYF1647).

Availability of data and materials
All data generated or analyzed during this study are included in this article.

Ethics approval and consent to participate
Informed consent was obtained from each participant. This research was in compliance with the Declaration of Helsinki and approved by the ethics committee of West China Hospital of Sichuan University.

Consent for publication
Not applicable.

Competing interests
The authors declare that they have no competing interests.

Author details
1 Division of Nephrology, West China Hospital, Sichuan University, Chengdu, China. 2 Division of Nephrology, The First Hospital of Fuzhou City, Fujian Medical University, Fuzhou, China. 3 Department of Nephrology, West China Hospital, Sichuan University, 37th Guoxuexiang Road, Chengdu 610041, China.

Received: 23 July 2019   Accepted: 25 November 2019

Published online: 03 December 2019

References
1. Zhou FD, Zhao MH, Zou WZ, Liu G, Wang H. The changing spectrum of primary glomerular diseases within 15 years: a survey of 3331 patients in a single Chinese centre. Nephrol Dial Transplant. 2009;24:870–6.
2. D’Amico G. Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors. Am J Kidney Dis. 2000;36:227–37.
3. Mulay SR, Evan A, Anders HJ. Molecular mechanisms of crystal-related kidney inflammation and injury: Implications for cholesterol embolism, crystalline nephropathies and kidney stone disease. Nephrol Dial Transpl. 2014;29:507–14.
4. Fu R, Guo C, Wang S, Huang Y, Jin Q, Hu H, Chen J, Xu B, Zhou M, Zhao J, et al. Podocyte activation of NLRP3 inflammasomes contributes to the development of proteinuria in lupus nephritis. Arthritis Rheumatol. 2017;69:1636–46.
5. Shigeoka AA, Mueller JL, Kambo A, Mathison JC, King AJ, Hall WF, Correia Jda S, Ulevitch RJ, Hoffman JM, McKay DB. An inflammasome-independent role for epithelial-expressed Nlrp3 in renal ischemia-reperfusion injury. J Immunol. 2010;185:6277–85.
6. Xiong J, Wang Y, Shao N, Gao P, Tang H, Su H, Zhang C, Meng XF. The expression and significance of NLRP3 inflammasome in patients with primary glomerular diseases. Kidney Blood Press Res. 2015;40:344–54.
7. Li G, Chen Z, Bhat QM, Zhang Q, Abais-Battad JM, Conley SM, Ritter JK, Li PL. NLRP3 inflammasome as a novel target for docosahexaenoic acid metabolites to abrogate glomerular injury. J Lipid Res. 2017;58:1080–90.
8. Menon MC, Chuang PY, He JC. Role of podocyte injury in IgA nephropathy. Contrib Nephrol. 2013;181:41–51.
9. Goldwich A, Burkard M, Olke M, Daniel C, Amann K, Hugo C, Kurts C, Steinackerer A, Gessner A. Podocytes are non hematopoietic professional antigen-presenting cells. J Am Soc Nephrol. 2013;24:906–16.
10. Wang C, Ye Z, Peng H, Tang H, Liu X, Chen Z, Yu X, Lou T. Effect of aggregated immunoglobulin A1 from immunoglobulin A nephropathy patients on nephrin expression in podocytes. Nephrology (Carlton). 2009;14:213–8.
11. Wang C, Peng H, Tang H, Liu X, Chen Z, Lou T, Yu X. Serum IgA1 from IgA nephropathy patients induces apoptosis in podocytes through direct and indirect pathways. Clin Invest Med. 2007;30:E240–9.
12. Yang L, Zhang X, Peng W, Wei M, Qin W. MicroRNA-135-induced T lymphocyte subgroup grading in IgA nephropathy. Int Urol Nephrol. 2017;49:553–61.
13. Huang X, Xue H, Ma J, Zhang Y, Zhang J, Liu Y, Qin X, Sun C. Salidroside ameliorates Adriamycin nephropathy in mice by inhibiting beta-catenin activity. J Cell Mol Med. 2019;23:4443–53.
14. Ji L, Chen X, Zhong X, Li Z, Yang L, Fan J, Tang W, Qin W. Astragalus membranes up-regulate Cosmic expression and reverse IgA dys-glycosylation in IgA nephropathy. BMC Compl Altern Med. 2014;14:195.
15. Zhao J, Rui HL, Yang M, Sun LJ, Dong HB, Cheng H. CD36-mediated lipid accumulation and activation of NLRP3 inflammasome lead to podocyte injury in obesity-related glomerulopathy. Mediat Inflamm. 2019;2019;2019:372647.
16. Gao P, He FF, Tang H, Lei CT, Chen S, Meng XF, Su H, Zhang C. NADPH oxidase-induced NALP3 inflammasome activation is driven by the edoxin-interacting protein which contributes to podocyte injury in hyperglycemia. J Diabetes Res. 2015;2015:504761.
17. Zhang C, Boini KM, Xia M, Abais JM, Li X, Liu Q, Li PL. Activation of Nod-like receptor protein 3 inflammasomes turns on podocyte injury and glomerular sclerosis in hyperfibrinogenemia. Hypertension. 2011;260:154–62.
18. Schroeder K, Tischopp J. The inflammasomes. Cell. 2010;140:821–32.
19. Chun J, Chung H, Wang X, Barry R, Taheri ZM, Pfaffl MJ, Ahmed SB, Trpkov K, Hemmelgarn B, Benedictsson H, et al. NLRP3 localizes to the
tubular epithelium in human kidney and correlates with outcome in IgA nephropathy. Sci Rep. 2016;6:24667.

20. Wang W, Wang X, Chun J, Villaysane A, Clark S, French G, Bracey NA, Trpkov K, Bonni S, Duff HJ, et al. Inflammasome-independent NLRP3 augments TGF-beta signaling in kidney epithelium. J Immunol. 2013;190:1239–49.

21. Banas MC, Banas B, Hudkins KL, Wietecha TA, Iyoda M, Bock E, Hauser P, Pippin JW, Shankland SJ, Smith KD, et al. TLR4 links podocytes with the innate immune system to mediate glomerular injury. J Am Soc Nephrol. 2008;19:704–13.

22. Lorenz G, Darisipudi MN, Anders HJ. Canonical and non-canonical effects of the NLRP3 inflammasome in kidney inflammation and fibrosis. Nephrol Dial Transplant. 2014;29:41–8.

23. Anders HJ, Suarez-Alvarez B, Grigorescu M, Foresto-Neto O, Steiger S, Desai J, Marschner JA, Honarpisheh M, Shi C, Jordan J, et al. The macrophage phenotype and inflammasome component NLRP3 contributes to nephrocalcinosis-related chronic kidney disease independent from IL-1-mediated tissue injury. Kidney Int. 2018;93:656–69.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.